Search icon

TAURUS DIAGNOSTICS, INC.

Company Details

Name: TAURUS DIAGNOSTICS, INC.
Jurisdiction: New York
Legal type: FOREIGN BUSINESS CORPORATION
Status: Active
Date of registration: 03 Feb 2021 (4 years ago)
Entity Number: 5932883
ZIP code: 13202
County: Onondaga
Place of Formation: Delaware
Address: 351 SOUTH WARREN STREET, SYRACUSE, NY, United States, 13202

DOS Process Agent

Name Role Address
THE CORPORATION DOS Process Agent 351 SOUTH WARREN STREET, SYRACUSE, NY, United States, 13202

Filings

Filing Number Date Filed Type Effective Date
210203000144 2021-02-03 APPLICATION OF AUTHORITY 2021-02-03

USAspending Awards / Financial Assistance

Date:
2022-02-18
Awarding Agency Name:
National Science Foundation
Transaction Description:
SBIR PHASE I: AI-BASED SYSTEM FOR ANALYZING MULTIPARAMETRIC MRI SCANS FOR PROSTATE LESION DETECTION -THE BROADER IMPACT/COMMERCIAL POTENTIAL OF THE SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE I PROJECT WILL BE TO IMPROVE PROSTATE CANCER DIAGNOSTICS. THIS PROJECT PROPOSES AN ARTIFICIAL INTELLIGENCE (AI)-BASED PLATFORM THAT OVERCOMES CURRENT SHORTCOMINGS WITH MANUAL MAGNETIC RESONANCE IMAGING (MRI) ASSESSMENT, CURRENTLY CONDUCTED ON HIGH-QUALITY MACHINES WITH RESULTS READ BY EXPERT RADIOLOGISTS AT A FEW LOCATIONS AROUND THE COUNTRY. AI ENABLES MRI ANALYSIS THAT IS AUTOMATED, STANDARDIZED, AND MORE ACCURATE. THIS WILL REDUCE UNNECESSARY AND INVASIVE BIOPSY AND/OR TREATMENT FOR LOW-RISK PROSTATE CANCERS, AS WELL AS PHYSICIAN TIME AND EFFORT TO RUN AND READ MRIS. FURTHERMORE, IT WILL ENABLE NON-EXPERT CENTERS TO ACCURATELY DIAGNOSE PATIENTS WITHOUT REQUIRING EXTENSIVE TESTING, TOP-TIER MRI EQUIPMENT, OR INVASIVE SURGERY. THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE I PROJECT DEVELOPS A NOVEL PROSTATE CANCER DIAGNOSTIC PLATFORM THAT LEVERAGES THE POWER OF AI-BASED IMAGE ANALYSIS FOR HIGH SENSITIVITY AND SPECIFICITY. WHILE PROSTATE CANCER DIAGNOSTICS RELY HEAVILY ON MRIS, THE ACCURACY OF THESE ASSESSMENTS DEPENDS ON BOTH EXPERT EXPERIENCE AND MRI QUALITY. THE MACHINE LEARNING SOLUTION IS ABLE TO MAKE GLOBAL ASSESSMENTS ON THE LIKELIHOOD OF DETECTED LESIONS BEING CLINICALLY SIGNIFICANT (I.E., GLEASON 3+4/GRADE GROUP 2 OR HIGHER), BETTER INFORMING CLINICIANS ON APPROPRIATE TREATMENT. THIS PROJECT PROPOSES THE FOLLOWING TECHNOLOGY DEVELOPMENT OBJECTIVES: 1) DEVELOP A METHOD TO MEASURE MRI QUALITY, 2) CREATE A GENERATIVE ADVERSARIAL NETWORK (GAN) FRAMEWORK TO REPAIR IMAGES FROM POOR TO HIGHER QUALITY, AND 3) PROSPECTIVELY EVALUATE NEW FRAMEWORK TO MEASURE THE OVERALL PERFORMANCE OF THE AI ALGORITHM. THIS AWARD REFLECTS NSF'S STATUTORY MISSION AND HAS BEEN DEEMED WORTHY OF SUPPORT THROUGH EVALUATION USING THE FOUNDATION'S INTELLECTUAL MERIT AND BROADER IMPACTS REVIEW CRITERIA.
Obligated Amount:
256000.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00

Date of last update: 22 Mar 2025

Sources: New York Secretary of State